Multicentre randomised trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone bcell lymphoma of mucosa associated lymphoid tissue (malt lymphoma).

Trial Profile

Multicentre randomised trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone bcell lymphoma of mucosa associated lymphoid tissue (malt lymphoma).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Chlorambucil (Primary) ; Rituximab (Primary)
  • Indications Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2017 Results of a MALT lymphoma prognostic index generated using data from 401 patients enrolled in this trial, published in the Blood.
    • 29 Mar 2017 Results published in the Journal of Clinical Oncology
    • 18 Oct 2013 Additional lead trial centre added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top